



Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 24 December 2019 – 07:30 CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 1,444,250 new shares on 20 December 2019, in execution of the principle agreement concluded on 30 September with the former owners of Uteron Pharma relating to the remaining payment obligations that Mithra has under the current earnout agreement.¹

Following this capital increase, Mithra now has 39,133,245 outstanding shares carrying voting rights (37,688,995 outstanding shares previously).

Therefore, Mithra publishes the updated following information :

- Share capital: EUR 28,649,330.65
- Total number of securities carrying voting rights: 39,133,245 (all ordinary shares)
- Total number of voting rights (= denominator): 39,133,245 (all relating to ordinary shares)
- Number of rights to subscribe securities carrying voting rights not yet issued :
 - Pursuant to the warrant plan of 2 March 2015: 620 warrants giving right to 1,023,000 shares
 - Pursuant to the warrant plan of 5 November 2018 and following the offer of new subscription rights for new members of the Management Team: 1,333,395 warrants giving right to 1,333,395 shares

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its three lead development candidates – a fifth generation oral contraceptive Estelle®, the first complete oral treatment for perimenopause PeriNesta™ and next-generation hormone therapy Donesta® - are built on Mithra's

¹ Press release Mithra "[Mithra successfully renegotiates Earnout Payments](#)", 01/10/2019

unique native estrogen platform, E4 (Estetrol). Mithra also develops and manufactures complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To receive our press releases by email, please subscribe to our mailing list on investors.mithra.com